Recent Posts in ‘Headline’
Pressure BioSciences (PBIO): Favorable Financing and Board Changes Signal Commercialization, Progress
Pressure BioSciences, Inc. (OTCQB: PBIO) is a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), which it provides to companies like Thermo Fisher Scientific (NYSE: TMO), Amgen Inc. (NASDAQ: AMGN) and other medical and biotechnology companies around the world. We have been following them for some
Pressure BioSciences (PBIO): A Game-Changing Technology Platform
Pressure BioSciences Inc. (NASDAQ: PBIO) is a developer of proprietary laboratory instrumentation and associated consumables based on its game-changing Pressure Cycling Technology (PCT), competing against other companies in the sample preparation technology sector, like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and Co. (NYSE: BDX). Simplifying and Improving Sample Preparation Lab sample preparation is often
Immunocellular Therapeutics (IMUC): Targeting Cancer Stem Cells
Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike similar companies, such as ImmunoGen Inc. (NASDAQ: IMGN) and Dendreon Corp. (NASDAQ: DNDN), IMUC is developing immunotherapies that target cancer stem cells in addition to normal cancer cells as a means to delay and prevent cancer
Amarantus BioSciences (AMBS) Presents Data for Parkinson’s Program
Amarantus BioSciences Inc. (OTCBB: AMBS), a biotechnology company focused on a therapeutic protein that addresses apoptosis, similar to companies like Generex Biotechnology Corporation (OTCBB: GNBT) and Roche Holdings Ltd. (Pink Sheets: RHHBY), recently presented data for its Parkinson’s Disease program. Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein
$1.5M in Grant Funding to Benefit Nuvilex (NVLX) via SG Austria Acquisition
Nuvilex Inc. (OTCQB: NVLX), an innovative biotechnology and natural products company with a promising oncology treatment based on live-cell encapsulation technology, similar to companies like PDL BioPharma Inc. (Nasdaq: PDLI) and Vertex Pharmaceuticals Inc. (Nasdaq:VRTX), will benefit from grant funding previously awarded to SG Austria for it’s live-cell encapsulation activities. SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Nuvilex, Inc. (OTCQB:
Nuvilex (OTCQB: NVLX) Featured as The Green Baron Report’s 2011 Stock Pick of the Year
Nuvilex Inc. (OTCQB: NVLX), a Green Company believing in “Good for You, Good for the Environment”, is focusing its direction toward multi-billion dollar bio-tech sectors, similar to companies like PDL BioPharma Inc. (Nasdaq: PDLI) and Vertex Pharmaceuticals Inc. (Nasdaq:VRTX), recently announced that it was featured as The Green Baron Report’s 2011 Stock Pick of the
Provectus (OTCBB: PVCT) Reports on Second End-of-Phase 2 Meeting with FDA to Define Pathway to Licensure of PV-10 for Metastatic Melanoma
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a biopharmaceutical company focused on developing treatments for cancer and psoriasis based on the Rose Bengal compound, similar to companies like Dendreon Corporation (Nasdaq: DNDN) and Geron Corporation (Nasdaq: GERN), recently reported on its second end-of-phase 2 meeting with the FDA to define a pathway to licensure of its PV-10
Athersys (Nasdaq: ATHX) Develops MultiStem for Bone Marrow Transplants
Athersys Inc. (Nasdaq: ATHX), a clinical-stage biopharmaceutical company focused on a number of different therapeutic candidates, similar to companies like StemCells, Inc. (Nasdaq: STEM) and Genzyme Corporation (Nasdaq: GENZ), is developing its MultiStem product to help bone marrow transplant patients. For many types of cancer, such as leukemia or other blood-borne cancers, treatment typically involves
Repros Therapeutics (Nasdaq: RPRX) Gets Back on Track with Androxal
Repros Therapeutics Inc. (Nasdaq: RPRX), which is developing male and female reproductive health products alongside companies like Eli Lilly & Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT), appears to be back on track with its Androxal® and Proellex® treatments after a somewhat turbulent past dotted with FDA disagreements and liver toxicity – so is
Iris BioTechnologies (IRSB) Lands New Patents
Iris Biotechnologies Inc. (IRSB), operating in the emerging personalized medicine industry alongside companies like Genomic Health, Inc. (GHDX) and SenoRx, Inc. (SENO), added two new Canadian patents to its growing portfolio. Iris BioTechnologies Inc. (OTCBB: IRSB), a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions,